Clovis Oncology
Rucaparib, a PARP inhibitor small-molecule therapeutic for ovarian and prostate cancer, alone and in combination with atezolizumab
- Sector
- Biotech
- Headquarters
- BOULDER, CO
- Founded
- 2009
- Latest Form D
- $192M, Nov 2013
- Total capital
- $505M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $505M
- 4 Form D · last Nov 2013
- 155 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 22 pending · first 2018
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$192M
- Private capital raisedForm D · SEC · 3rd filing$20M
- Private capital raisedForm D · SEC · 2nd filing$146M
- Private capital raisedForm D · SEC · 1st filing$146M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew R. AllenExecutive OfficerNamed in SEC Form D filings
- Brian G. AtwoodDirectorNamed in SEC Form D filings
- Edward J. McKinleyDirectorNamed in SEC Form D filings
- Erle T. MastExecutive OfficerNamed in SEC Form D filings
- Gillian C. Ivers-ReadExecutive OfficerNamed in SEC Form D filings
- Ginger L. GrahamDirectorNamed in SEC Form D filings
Show all 13 people
- James C. BlairDirectorNamed in SEC Form D filings
- Keith L. FlahertyDirectorNamed in SEC Form D filings
- M. James BarretDirectorNamed in SEC Form D filings
- Patrick J. MahaffyExecutive OfficerNamed in SEC Form D filings
- Paul C. KlingensteinDirectorNamed in SEC Form D filings
- Steven L. HoerterExecutive OfficerNamed in SEC Form D filings
- Thorlef J. SpickschenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 24- PendingImmunostimulatory Agents In Combination With Angiogenesis InhibitorsUSPTOApplication 17231307
- PendingHigh Dosage Strength Tablets of RucaparibUSPTOApplication 16154038
- GrantedHigh Dosage Strength Tablets of RucaparibUSPTOUS 10,130,636
Show all 24 patent records
- Immunostimulatory Agents In Combination With Angiogenesis InhibitorsNov 4, 2021 · Application 17231307Pending
- High Dosage Strength Tablets of RucaparibApr 4, 2019 · Application 16154038Pending
- High Dosage Strength Tablets of RucaparibNov 20, 2018 · US 10,130,636Granted
- Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of HeterozygosityJun 14, 2018 · Application 15104684Pending
- High Dosage Strength Tablets of RucaparibJun 5, 2018 · US 9,987,285Granted
- Salts of an Epidermal Growth Factor Receptor Kinase InhibitorMar 17, 2016 · Application 14784503Pending
- Immunostimulatory Agents in Combination with Angiogenesis InhibitorsApplication 63010185Pending
- Methods For Administering Lucitanib And Combinations ThereofApplication 62959339Pending
- Methods For Administering Lucitanib And Combinations ThereofApplication PCTUS2021012672Pending
- Therapeutic Combinations For Treating CancerApplication PCTUS2016024839Pending
- Growth Factor Receptor InhibitorsApplication PCTUS2015046089Pending
- Immunostimulatory Agents In Combination With Angiogenesis InhibitorsApplication PCTUS2021027507Pending
- High Dosage Strength Tablets Of RucaparibApplication PCTUS2015045522Pending
- Therapeutic Combinations for Treating CancerApplication 62145055Pending
- Therapeutic Combinations For Treating CancerApplication PCTUS2015012442Pending
- Use Of Parp Inhibitors To Treat Breast Or Ovarian Cancer Patients Showing A Loss Of HeterozygosityApplication PCTUS2015011413Pending
- High Dosage Strength Tablets of RucaparibApplication 62101739Pending
- Growth Factor Receptor InhibitorsApplication 62081300Pending
- Use Of Parp Inhibitors To Treat Breast Or Ovarian Cancer Patients Showing A Loss Of HeterozygosityApplication 62076165Pending
- Insulin-Like Growth Factor Receptor InhibitorsApplication 62040625Pending
- High Dosage Strength Tablets of RucaparibApplication 62040849Pending
- Use Of Parp Inhibitors To Treat Breast Or Ovarian Cancer Patients Showing A Loss Of HeterozygosityApplication 62039516Pending
- Methods For Administering Lucitanib And Combinations ThereofApplication 63077158Pending
- Use Of Parp Inhibitors To Treat Breast Or Ovarian Cancer Patients Showing A Loss Of HeterozygosityApplication 62004424Pending
Related companies, and why
- LongRun P.B.C.Similar federal contract value in Biotech · null in contracts
- Zacharon Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Foment Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Arteriocyte Medical Systems IncSimilar federal contract value in Biotech · null in contracts
- Carcinotech Ltd.Similar federal contract value in Biotech · null in contracts
- Xaira TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .